---
title: "Top Executive Makes Major Move With Butterfly Network Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284952317.md"
description: "Butterfly Network's Chief Business Officer, Steve Cashman, sold 147,518 shares valued at $722,838 on May 1, 2026, raising investor interest regarding executive sentiment. The company reported strong Q1 results with revenue and margins exceeding expectations, alongside improved cash burn. Analysts maintain a Neutral outlook on BFLY stock due to weak profitability and ongoing losses, despite positive growth signals and FDA clearance for a new AI tool. The stock has a year-to-date performance of 26.05% and a market cap of $1.22B."
datetime: "2026-05-02T02:05:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284952317.md)
  - [en](https://longbridge.com/en/news/284952317.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284952317.md)
---

# Top Executive Makes Major Move With Butterfly Network Shares

New insider activity at Butterfly Network ( (BFLY) ) has taken place on May 1, 2026.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Butterfly Network’s Chief Business Officer, Steve Cashman, has unloaded a substantial block of company shares, selling 147,518 units of Butterfly Network stock in a transaction valued at $722,838. This insider move may draw investor attention as market watchers assess what this sizable sale could signal about executive sentiment and the company’s near-term prospects.

**Recent Updates on BFLY stock**

Butterfly Network shares reacted to a strong Q1 update, where revenue and margins beat expectations and cash burn improved, supporting a narrative of accelerating growth and better operating leverage. Analysts’ outlooks and any price target shifts appear driven by this upside versus consensus, the rapid expansion of the Embedded business, and growing software and AI traction.

Sentiment was further supported by FDA clearance of a gestational age AI tool, expanding regulatory validation for Butterfly’s platform, and by guidance that points to sustained double‑digit growth despite ongoing losses. Appointment of a new CMO for point‑of‑care ultrasound, plus clearer multi‑year product and Home & Community Care roadmaps, reinforced confidence in execution while keeping attention on profitability timing and regulatory and concentration risks.

**Spark’s Take on BFLY Stock**

According to Spark, TipRanks’ AI Analyst, BFLY is a Neutral.

The score is held back primarily by weak profitability and continued cash burn despite improving trends and a low-debt balance sheet. Technicals are moderately supportive, while the earnings call added positives around growth, margin expansion, and reiterated guidance. Valuation remains a constraint because the company is still loss-making and offers no dividend yield.

To see Spark’s full report on BFLY stock, click here.

**More about Butterfly Network**

**YTD Price Performance:** 26.05%

**Average Trading Volume:** 5,909,702

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $1.22B

### Related Stocks

- [BFLY.US](https://longbridge.com/en/quote/BFLY.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [BFLY+.US](https://longbridge.com/en/quote/BFLY+.US.md)
- [BFLYW.US](https://longbridge.com/en/quote/BFLYW.US.md)

## Related News & Research

- [Assessing Butterfly Network (BFLY) Valuation After Recent Volatility And Handheld Ultrasound Momentum](https://longbridge.com/en/news/285826052.md)
- [Jenscare’s LuX-Valve Plus Shows Strong One-Year Results in Large Annulus Tricuspid Patients](https://longbridge.com/en/news/287144318.md)
- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [Lifeward Delays Quarterly Report Amid Deal Accounting](https://longbridge.com/en/news/286586728.md)
- [Orthofix Medical updates 2026 outlook after CMS Medicare cuts for bone growth stimulators](https://longbridge.com/en/news/287216169.md)